Literature DB >> 16485129

Complement decay accelerating factor (DAF)/CD55 in cancer.

Ian Spendlove1, Judith M Ramage, Richard Bradley, Claire Harris, Lindy G Durrant.   

Abstract

The complement system is a powerful innate mechanism involved in protection of the host against pathogens. It also has a role in the clearance of apoptotic cells and has been implicated in a range of pathologies including autoimmunity and graft rejection. The control of complement is mediated through the complement regulatory proteins (CRPs). These are present on most cells and protect normal cells from complement-mediated attack during innate activation. However, in a range of pathologies and cancer, these molecules are up or down regulated, sometimes secreted and even lost. We will review the expression of CRPs in cancer, focussing on CD55 and highlight other roles of the CRPs and their involvement in leukocyte function. We will also provide some data providing a potential mechanism by which soluble CD55 can inhibit T-cell function and discuss some of the implications of this data.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16485129     DOI: 10.1007/s00262-006-0136-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  19 in total

1.  The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma.

Authors:  Shao-Liang Han; Chang Xu; Xiu-Ling Wu; Jun-Lin Li; Zhi Liu; Qi-Qiang Zeng
Journal:  Int J Colorectal Dis       Date:  2010-03-26       Impact factor: 2.571

Review 2.  Complement regulators and inhibitory proteins.

Authors:  Peter F Zipfel; Christine Skerka
Journal:  Nat Rev Immunol       Date:  2009-09-04       Impact factor: 53.106

3.  Decay accelerating factor (CD55)-mediated attenuation of complement: therapeutic implications for age-related macular degeneration.

Authors:  Kelly N Ma; Siobhan M Cashman; J Harry Sweigard; Rajendra Kumar-Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-08-04       Impact factor: 4.799

Review 4.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

Review 5.  Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 6.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07

Review 7.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

8.  Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.

Authors:  Lacey Gunn; Chuanlin Ding; Min Liu; Yunfeng Ma; Chunjian Qi; Yihua Cai; Xiaoling Hu; Deep Aggarwal; Huang-Ge Zhang; Jun Yan
Journal:  J Immunol       Date:  2012-08-22       Impact factor: 5.422

9.  The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma.

Authors:  Daren Liu; Bogusz Trojanowicz; Longyun Ye; Chao Li; Luqing Zhang; Xiaowen Li; Guogang Li; Yixiong Zheng; Li Chen
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Complement susceptibility in glutamine deprived breast cancer cells.

Authors:  Bradley S Ellison; Mary Kb Zanin; Robert J Boackle
Journal:  Cell Div       Date:  2007-07-11       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.